← All trials
NCT06126861
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Feb 10, 2024
- Completion date
- Feb 28, 2024
- First posted
- Nov 13, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Soochow UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.